ArticleFood science & nutrition2026
Jiawei Danxuan Koukang and Its Component Kaempferol Alleviate Oral Submucous Fibrosis by Restoring Epithelial-Fibroblast Homeostasis and Suppressing Neutrophil Recruitment via the ANXA1/FPR2 Axis.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heterogeneous mechanisms, risk stratification, and translational advances in the malignant transformation of oral potentially malignant disorders to oral squamous cell carcinoma.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral submucous fibrosis (OSF) is a betel quid chewing-associated precancerous disorder. Studies have shown that the traditional Chinese medicine Jiawei Danxuan Koukang (JDK) exhibits inhibitory effects on OSF, but its specific mechanisms and molecular targets remain unstated. This study aims to elucidate the pharmacological mechanisms of JDK and its component kaempferol in treating OSF. OSF rat model and in vitro cell models were induced by arecoline. Techniques, including hematoxylin-eosin (HE) staining, Masson staining, western blot, quantitative real-time polymerase chain reaction (qRT-PCR), enzyme-linked immunosorbent assay (ELISA), immunofluorescence (IF) staining, co-immunoprecipitation (Co-IP), and molecular docking were used to evaluate the effects of JDK and kaempferol on OSF pathological damage, Annexin-A1 (ANXA1) expression, neutrophil infiltration, collagen deposition, and fibroblast activation. JDK and kaempferol alleviated pathological damage in the oral mucosa tissues of OSF rats, inhibited collagen deposition and fibroblast activation marker expressions, including fibroblast activation protein (FAP), vimentin (VIM), alpha-smooth muscle actin (α-SMA), and matrix metalloproteinase-1 (MMP1), and improved mouth opening function. Further studies revealed that JDK and kaempferol upregulated ANXA1 expression, thereby suppressing neutrophil recruitment, pro-inflammatory cytokine release, and collagen deposition. In vitro experiments confirmed that kaempferol directly bound to ANXA1 in epithelial cells, enhancing its stability, and interacted with FPR2 signaling in fibroblasts to inhibit their activation, thereby restoring epithelial-fibroblast homeostasis. However, knockdown of ANXA1 reversed these protective effects. JDK and kaempferol attenuated OSF by upregulating the ANXA1/FPR2 axis, inhibiting neutrophil infiltration and fibroblast activation, suggesting ANXA1 as a potential therapeutic target for OSF. To our knowledge, this is the first study to demonstrate that JDK/kaempferol exert anti-fibrotic effects in OSF specifically through the ANXA1/FPR2 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.